Who is eligible for clinical trial NCT07011719?

Participants must meet protocol criteria for Metastatic Clear Cell Renal Cell Carcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07011719 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-29

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT07011719)

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Arcus Biosciences, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Who can join: Review the eligibility criteria below.

Location: Research Site — Gilbert, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (159 Sites)

Showing the first 25 of 159 sites.

Research Site — Gilbert, Arizona
Research Site — Goodyear, Arizona
Research Site — Phoenix, Arizona
Research Site — Duarte, California
Research Site — Irvine, California
Research Site — La Jolla, California
Research Site — Los Angeles, California
Research Site — Sacramento, California
Research Site — San Diego, California
Research Site — New Haven, Connecticut
Research Site — Washington D.C., District of Columbia
Research Site — Jacksonville, Florida
Research Site — Miami, Florida
Research Site — Orlando, Florida
Research Site — Atlanta, Georgia
Research Site — Atlanta, Georgia
Research Site — Newnan, Georgia
Research Site — Zion, Illinois
Research Site — Indianapolis, Indiana
Research Site — Louisville, Kentucky
Research Site — Jefferson, Louisiana
Research Site — Baltimore, Maryland
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts
Research Site — Rochester, Minnesota

📞 Contact the Study Coordinator

Phone: (510) 462-3330

Email: clinicaltrials@arcusbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Clear Cell Renal Cell Carcinoma

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy — Duarte, California
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial — Birmingham, Alabama
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) — New York, New York

Explore by condition: All Metastatic Clear Cell Renal Cell Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗